<article id="weyckler_2009" class="slide" data-ag-slide-name="Weyckler 2009">
    <div class="basic">
      <h1 data-ag-editable="Weycker 2009 Main Title">Neulasta<sup>®</sup> just once per cycle* provides a tailored way to reduce 
your patient’s risk of neutropenia-related hospitalisation<sup>1</sup></h1>
      <div id="fn_page3_graph1"></div>
      <div id="fn_page_right_data">
         <h2 data-ag-editable="Weycker 2009 Sub Title 1">Hospital admission</h2>
         <p data-ag-editable="Weycker 2009 Copy 1">With a diagnosis (primary or secondary) 
of neutropenia or fever is</p>
         <h2 data-ag-editable="Weycker 2009 Sub Title 2">36% less likely</h2>
         <p data-ag-editable="Weycker 2009 Copy 2">with Neulasta<sup>®</sup> compared to filgrastim<sup>1</sup></p>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="weyckler_2009_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Weycker 2009 References Title">References:</strong></p>
          <div data-ag-editable="Weycker 2009 References List">
             <ol>
                <li>Weycker D <em>et al</em>. Risk of Hospitalisation for Neutropenic Complications of Chemotherapy 
   in Patients With Primary Solid Tumors Receiving Pegfilgrastim or Filgrastim Prophylaxis: 
   A Retrospective Cohort Study. Clin Ther 2009; 31(5):1069-1081</li>
                
             </ol>
          </div>
          <p data-ag-editable="Weycker 2009 References Bottom Copy">* 24 hours after chemotherapy, Neulasta SmPC October 2011<br /><br />
          Retrospective cohort study of 4903 patients with breast, Non-Hodgkin’s Lymphoma, lung and other malignancies. Data were obtained from US medical and claim databases from 15,763 patients who received a course of chemotherapy between 2003 and 2005 and had a medical or pharmacy claim for pegfilgrastim or filgrastim at any time.</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>